


3. 点击视图最右侧“View”（查阅）按键，即可查阅交易概要。



The image shows a 'View' button in a light blue box. A blue arrow points from this button to the 'Deal Details' modal window. The modal window has a title bar with a close button (X). It contains two main sections: 'Events' and 'Sources'.

Deal Details

Events

30-Jul-2002 - In July 2002, Abbott Laboratories entered an agreement with Triangle Pharmaceuticals to manufacture and commercially supply emtricitabine worldwide.- Abbott was expected to manufacture sufficient amounts for the first year's sales and would supply additional material through July 31, 2005 at Triangle's request.- Abbott would provide resources to transfer the manufacturing process for emtricitabine to a third-party manufacturer.- In exchange for these rights Triangle would forego rights to all remaining milestones and the right to co-promote Abbott's Kaletra in the US.- Abbott would receive \$8,784 per kilogram for the bulk drug, \$13,200 per kilogram for additional bulk drug orders received on or before December 31, 2002.- The price for additional bulk drugs ordered after December 31, 2002, would be 110% and for the 2003 calendar year would be \$12,838.- Abbott would receive \$3.471244 million, including \$1.471244 million on signing and \$2 million to be received on or before April 15, 2003.

Sources

Triangle Pharmaceuticals Inc, "Abbott Laboratories/Triangle Pharmaceuticals Inc FOIA Contract: Exhibit 10.3 from Form 8-K: SUPPLY AND MANUFACTURING AGREEMENT", CONTRACT, issue: September 19, 2002
Triangle Pharmaceuticals Inc, "Triangle Pharmaceuticals Inc Announces Reacquisition of Product Rights From Abbott Laboratories", Press Release, issue: July 30, 2002
Triangle Pharmaceuticals Inc;null, "Termination/Reacquisition", CONTRACT, issue: Jul 01, 2002

4. 欲了解更多信息，请与 **LS 产品支持** 客服联系